Brief Article
Copyright ©2012 Baishideng. All rights reserved.
World J Gastrointest Surg. Jun 27, 2012; 4(6): 135-140
Published online Jun 27, 2012. doi: 10.4240/wjgs.v4.i6.135
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion: The University of Arizona early experience
Ioannis T Konstantinidis, Christine Young, Vassiliki L Tsikitis, Ellyn Lee, Tun Jie, Evan S Ong
Ioannis T Konstantinidis, Christine Young, Vassiliki L Tsikitis, Tun Jie, Evan S Ong, Department of Surgery, The University of Arizona College of Medicine, 1501 N. Campbell Av. PO Box 245131, Tucson, AZ 85724-5131, United States
Ellyn Lee, Department of Medicine, The University of Arizona College of Medicine, 1501 N. Campbell Av. PO Box 245131, Tucson, AZ 85724-5131, United States
Author contributions: Konstantinidis IT wrote the manuscript; Young C provided the data; Tsikitis VL, Lee E and Jie T critically revised the manuscript; Ong ES conceived and designed the study and critically revised the manuscript
Correspondence to: Evan S Ong, MD, MS, Department of Surgery, The University of Arizona College of Medicine, 1501 N. Campbell Avenue, PO Box 245131, Tucson, AZ 85724-5058, United States. eong@surgery.arizona.edu
Telephone: +1-520-6264153 Fax: +1-520-6267138
Received: December 18, 2011
Revised: June 22, 2012
Accepted: June 24, 2012
Published online: June 27, 2012
Abstract

AIM: To evaluate the safety and effectiveness of our new cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) program.

METHODS: Retrospective review of patients with gastrointestinal malignancies who were suitable candidates for CRS and HIPEC between 12/1/2009 and 10/1/2010. All clinicopathologic data were reviewed with a special focus on the surgical outcome and the postoperative morbidity and mortality.

RESULTS: Fourteen patients were identified. Median age was 64 years; seven were female. The primary tumors were: colonic (29%), appendiceal (36%), peritoneal mesothelioma (14%), gastric (7%), adenocarcinoma of unknown primary (7%), and gastrointestinal stromal tumor (7%). Eleven patients (79%) received CRS/HIPEC, three for palliation. Three patients that did not undergo CRS/HIPEC had an average peritoneal cancer index (PCI) of 25. The eight patients that underwent curative CRS/HIPEC had an average PCI of 10 and a completeness of cytoreduction score of 0 (87.5%) or 1 (12.5%). Postoperative morbidity was 36%; the worst adverse event was Grade 3 ileus. Mortality rate was 0%.

CONCLUSION: CRS with HIPEC is safe and feasible at tertiary institutions with fledgling programs. PCI is an accurate predictor of surgical outcomes.

Keywords: Cytoreductive surgery; Hyperthermic intraperitoneal chemoperfusion; Peritoneal carcinomatosis; Early outcomes